-
Je něco špatně v tomto záznamu ?
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
E. Terpos, P. Musto, M. Engelhardt, M. Delforge, G. Cook, F. Gay, NWCJ. van de Donk, I. Ntanasis-Stathopoulos, AJ. Vangsted, C. Driessen, F. Schjesvold, C. Cerchione, S. Zweegman, R. Hajek, P. Moreau, H. Einsele, J. San-Miguel, M. Boccadoro, MA....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- COVID-19 * epidemiologie MeSH
- konsensus MeSH
- lidé MeSH
- mnohočetný myelom * terapie MeSH
- neutralizující protilátky MeSH
- pandemie MeSH
- SARS-CoV-2 MeSH
- sérologická léčba covidu-19 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In the post-pandemic COVID-19 period, human activities have returned to normal and COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an increased risk for breakthrough infections and severe COVID-19 outcomes, including hospitalization and death. The European Myeloma Network has provided an expert consensus to guide patient management in this era. Vaccination with variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4/5 strains, is essential as novel strains emerge and become dominant in the community. Boosters should be administered every 6-12 months after the last vaccine shot or documented COVID-19 infection (hybrid immunity). Booster shots seem to overcome the negative effect of anti-CD38 monoclonal antibodies on humoral responses; however, anti-BCMA treatment remains an adverse predictive factor for humoral immune response. Evaluation of the immune response after vaccination may identify a particularly vulnerable subset of patients who may need additional boosters, prophylactic therapies and prevention measures. Pre-exposure prophylaxis with tixagevimab/cilgavimab is not effective against the new dominant variants and thus is no longer recommended. Oral antivirals (nirmatrelvir/ritonavir and molnupiravir) and remdesivir are effective against Omicron subvariants BA.2.12.1, BA.4, BA.5, BQ.1.1 and/or XBB.1.5 and should be administered in MM patients at the time of a positive COVID-19 test or within 5 days post symptoms onset. Convalescent plasma seems to have low value in the post-pandemic era. Prevention measures during SARS-CoV-2 outbreaks, including mask wearing and avoiding crowded places, seem prudent to continue for MM patients.
CRUK Clinical Trials Unit Leeds Institute of Clinical Trial Research University of Leeds Leeds UK
Department of Hematology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark
Department of Hematology Erasmus MC Cancer Institute Rotterdam the Netherlands
Department of Hematology University Hospital Hotel Dieu Nantes France
Department of Internal Medicine 2 University Hospital of Würzburg Würzburg Germany
Department of Medical Oncology and Hematology Cantonal Hospital St Gallen St Gallen Switzerland
Department of Oncology University Hospital Leuven Leuven Belgium
KG Jebsen Center for B Cell Malignancies University of Oslo Oslo Norway
Oslo Myeloma Center Department of Hematology Oslo University Hospital Oslo Norway
Unit of Hematology and Stem Cell Transplantation AOUC Policlinico Bari Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011185
- 003
- CZ-PrNML
- 005
- 20230801132845.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-023-01920-1 $2 doi
- 035 __
- $a (PubMed)37142661
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Terpos, Evangelos $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. eterpos@med.uoa.gr $1 https://orcid.org/0000000151331422
- 245 10
- $a Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) / $c E. Terpos, P. Musto, M. Engelhardt, M. Delforge, G. Cook, F. Gay, NWCJ. van de Donk, I. Ntanasis-Stathopoulos, AJ. Vangsted, C. Driessen, F. Schjesvold, C. Cerchione, S. Zweegman, R. Hajek, P. Moreau, H. Einsele, J. San-Miguel, M. Boccadoro, MA. Dimopoulos, P. Sonneveld, H. Ludwig
- 520 9_
- $a In the post-pandemic COVID-19 period, human activities have returned to normal and COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an increased risk for breakthrough infections and severe COVID-19 outcomes, including hospitalization and death. The European Myeloma Network has provided an expert consensus to guide patient management in this era. Vaccination with variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4/5 strains, is essential as novel strains emerge and become dominant in the community. Boosters should be administered every 6-12 months after the last vaccine shot or documented COVID-19 infection (hybrid immunity). Booster shots seem to overcome the negative effect of anti-CD38 monoclonal antibodies on humoral responses; however, anti-BCMA treatment remains an adverse predictive factor for humoral immune response. Evaluation of the immune response after vaccination may identify a particularly vulnerable subset of patients who may need additional boosters, prophylactic therapies and prevention measures. Pre-exposure prophylaxis with tixagevimab/cilgavimab is not effective against the new dominant variants and thus is no longer recommended. Oral antivirals (nirmatrelvir/ritonavir and molnupiravir) and remdesivir are effective against Omicron subvariants BA.2.12.1, BA.4, BA.5, BQ.1.1 and/or XBB.1.5 and should be administered in MM patients at the time of a positive COVID-19 test or within 5 days post symptoms onset. Convalescent plasma seems to have low value in the post-pandemic era. Prevention measures during SARS-CoV-2 outbreaks, including mask wearing and avoiding crowded places, seem prudent to continue for MM patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a COVID-19 $x epidemiologie $7 D000086382
- 650 12
- $a mnohočetný myelom $x terapie $7 D009101
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a sérologická léčba covidu-19 $7 D000093522
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a pandemie $7 D058873
- 650 _2
- $a neutralizující protilátky $7 D057134
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Musto, Pellegrino $u Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy $u Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy $1 https://orcid.org/0000000332776594
- 700 1_
- $a Engelhardt, Monika $u Department of Hematology and Oncology, Interdisciplinary Cancer Center and Comprehensive Cancer Center Freiburg, University of Freiburg, Faculty of Freiburg, Freiburg, Germany $1 https://orcid.org/0000000304051676
- 700 1_
- $a Delforge, Michel $u Department of Oncology, University Hospital Leuven, Leuven, Belgium
- 700 1_
- $a Cook, Gordon $u CRUK Clinical Trials Unit, Leeds Institute of Clinical Trial Research, University of Leeds, Leeds, UK $1 https://orcid.org/0000000317170412 $7 mub2013774654
- 700 1_
- $a Gay, Francesca $u Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy $1 https://orcid.org/000000028619412X
- 700 1_
- $a van de Donk, Niels W C J $u Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Ntanasis-Stathopoulos, Ioannis $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000263289783
- 700 1_
- $a Vangsted, Annette Juul $u Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark $1 https://orcid.org/000000022131731X
- 700 1_
- $a Driessen, Christoph $u Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
- 700 1_
- $a Schjesvold, Fredrik $u Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway $u KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway $1 https://orcid.org/0000000310960569
- 700 1_
- $a Cerchione, Claudio $u Hematology Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy $1 https://orcid.org/0000000291045436
- 700 1_
- $a Zweegman, Sonja $u Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Hajek, Roman $u Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000169556267 $7 nlk20000083645
- 700 1_
- $a Moreau, Philippe $u Department of Hematology, University Hospital Hotel-Dieu, Nantes, France $1 https://orcid.org/0000000317808746
- 700 1_
- $a Einsele, Hermann $u Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany $1 https://orcid.org/0000000276800819
- 700 1_
- $a San-Miguel, Jesus $u Cancer Center Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain $1 https://orcid.org/0000000291834857 $7 xx0060803
- 700 1_
- $a Boccadoro, Mario $u Division of Hematology, University of Turin, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy $1 https://orcid.org/0000000181305209
- 700 1_
- $a Dimopoulos, Meletios A $u Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece $1 https://orcid.org/0000000189903254
- 700 1_
- $a Sonneveld, Pieter $u Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands $1 https://orcid.org/0000000208082237
- 700 1_
- $a Ludwig, Heinz $u Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria $1 https://orcid.org/0000000233028726
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 37, č. 6 (2023), s. 1175-1185
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37142661 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132841 $b ABA008
- 999 __
- $a ok $b bmc $g 1963523 $s 1197450
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 37 $c 6 $d 1175-1185 $e 20230504 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20230718
